Darunavir (Prezista) for HIV infection.
Darunavir (Prezista--Tibotec), a new protease inhibitor, has received accelerated approval from the FDA for use in combination therapy of human-immunodeficiency-virus (HIV) infection in previously treated adults. It is coadministered with low-dose ritonavir (Norvir), which increases its bioavailability.
D023241:Antiretroviral Therapy, Highly Active / Q000379:methods; D001682:Biological Availability; D001798:Blood Proteins / Q000378:metabolism; D051544:Cytochrome P-450 CYP3A / Q000378:metabolism; D065692:Cytochrome P-450 CYP3A Inhibitors; D000069454:Darunavir; D017277:Drug Approval; D004347:Drug Interactions; D024882:Drug Resistance, Viral; D000077560:Enfuvirtide; D015700:HIV Envelope Protein gp41 / Q000494:pharmacology / Q000627:therapeutic use; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000493:pharmacokinetics / Q000627:therapeutic use; D015497:HIV-1 / Q000187:drug effects / Q000235:genetics / Q000302:isolation & purification; D006801:Humans; D010446:Peptide Fragments / Q000494:pharmacology / Q000627:therapeutic use; D011485:Protein Binding / Q000187:drug effects; D012367:RNA, Viral / Q000097:blood / Q000235:genetics; D016032:Randomized Controlled Trials as Topic / Q000379:methods; D019438:Ritonavir / Q000494:pharmacology / Q000627:therapeutic use; D013449:Sulfonamides / Q000493:pharmacokinetics / Q000627:therapeutic use*; D013607:Tablets; D013997:Time Factors; D014481:United States; D019562:Viral Load
D001798:Blood Proteins; D065692:Cytochrome P-450 CYP3A Inhibitors; D015700:HIV Envelope Protein gp41; D017320:HIV Protease Inhibitors; D010446:Peptide Fragments; D012367:RNA, Viral; D013449:Sulfonamides; D013607:Tablets; D000077560:Enfuvirtide; D051544:Cytochrome P-450 CYP3A; D019438:Ritonavir; D000069454:Darunavir